BCL2 and acute myeloid leukemia: Indeed, a recent drug screening study demonstrated that AML with erythroid or megakaryocytic differentiation, such as M7, depend on BCL-XL rather than BCL-2, showing higher sensitivity to navitoclax and reduced sensitivity to venetoclax [49].